[go: up one dir, main page]

BRPI0509211A - uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética - Google Patents

uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética

Info

Publication number
BRPI0509211A
BRPI0509211A BRPI0509211-6A BRPI0509211A BRPI0509211A BR PI0509211 A BRPI0509211 A BR PI0509211A BR PI0509211 A BRPI0509211 A BR PI0509211A BR PI0509211 A BRPI0509211 A BR PI0509211A
Authority
BR
Brazil
Prior art keywords
pain
treatment
diabetic neuropathy
peptide compounds
compounds
Prior art date
Application number
BRPI0509211-6A
Other languages
English (en)
Inventor
Christine Rauschkolb-L Ffler
Brigite Koch
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of BRPI0509211A publication Critical patent/BRPI0509211A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USO DE COMPOSTOS DE PEPTìDEO PARA O TRATAMENTO DE DOR EM NEUROPATIA DIABéTICA. A presente invenção refere-se ao uso de compostos para o tratamento de dor em neuropatia diabética dolorosa, de preferência em polineuropatia sensória distal diabética.
BRPI0509211-6A 2004-03-26 2005-03-24 uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética BRPI0509211A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55649904P 2004-03-26 2004-03-26
EP04007360A EP1579858A1 (en) 2004-03-26 2004-03-26 Novel use of peptide compounds for treating pain in painful diabetic neuropathy
PCT/EP2005/003176 WO2005092313A1 (en) 2004-03-26 2005-03-24 Novel use of peptide compounds for treating pain in painful diabetic neuropathy

Publications (1)

Publication Number Publication Date
BRPI0509211A true BRPI0509211A (pt) 2007-08-28

Family

ID=34854637

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509211-6A BRPI0509211A (pt) 2004-03-26 2005-03-24 uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética

Country Status (15)

Country Link
US (1) US20060100157A1 (pt)
EP (2) EP1579858A1 (pt)
JP (1) JP2007530493A (pt)
CN (1) CN1938010B (pt)
AU (1) AU2005226928B2 (pt)
BR (1) BRPI0509211A (pt)
CA (1) CA2558311A1 (pt)
EA (1) EA012176B1 (pt)
MX (1) MXPA06010995A (pt)
NZ (1) NZ549668A (pt)
SG (1) SG151309A1 (pt)
TW (1) TW200701977A (pt)
UA (1) UA90467C2 (pt)
WO (1) WO2005092313A1 (pt)
ZA (1) ZA200607269B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US7794987B2 (en) 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
CA2562937A1 (en) 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
NZ552651A (en) 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
CA2652667A1 (en) * 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
AU2007260207B2 (en) 2006-06-15 2012-11-08 Ucb Pharma Gmbh Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP2099444A4 (en) * 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
WO2011037833A2 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US10786464B2 (en) * 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
CN103561727B (zh) 2010-12-02 2018-03-27 优时比制药有限公司 每日给药1次的拉科酰胺制剂
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US6589994B1 (en) * 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
DE60112766T2 (de) * 2000-08-17 2006-03-30 Teva Pharmaceutical Industries Ltd. Verwendung von Derivaten der Valproinsäureamide und 2-Valproinsäureamide zur Behandlung und Prävention von Schmerzen und/oder Kopfschmerzen
ES2348646T3 (es) * 2000-08-25 2010-12-10 Research Corporation Technologies, Inc. Aminoacidos anticonvulsionantes para el tratamiento de la neurosis obsesivo-compulsiva.
EP1243262B1 (en) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US7794987B2 (en) * 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
CA2562937A1 (en) * 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia

Also Published As

Publication number Publication date
US20060100157A1 (en) 2006-05-11
MXPA06010995A (es) 2007-04-16
EA200601777A1 (ru) 2007-02-27
NZ549668A (en) 2010-07-30
WO2005092313A1 (en) 2005-10-06
EP1737437A1 (en) 2007-01-03
EA012176B1 (ru) 2009-08-28
CA2558311A1 (en) 2005-10-06
AU2005226928B2 (en) 2010-05-13
JP2007530493A (ja) 2007-11-01
TW200701977A (en) 2007-01-16
EP1579858A1 (en) 2005-09-28
ZA200607269B (en) 2008-04-30
CN1938010A (zh) 2007-03-28
UA90467C2 (ru) 2010-05-11
SG151309A1 (en) 2009-04-30
CN1938010B (zh) 2011-01-19
AU2005226928A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
BRPI0509211A (pt) uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
BRPI0810354A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
BRPI0615150A2 (pt) agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
GB0420888D0 (en) Compounds and uses
BRPI0518829A2 (pt) mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas
BRPI0409955A (pt) uso de antibióticos hìbridos de oxazolidinona - quinolina para o tratamento de antrax e outras infecções
MY148459A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
WO2008105088A1 (ja) 脊髄損傷治療薬剤
BRPI0516519A (pt) formulações de cuidado do cabelo compreendendo poliorganossiloxano aminofuncional
MX2009004770A (es) Compuestos de carbamato para usarse en el tratamiento de la depresion.
BRPI0606822A2 (pt) composto, métodos para preparar um composto e para tratar dor e/ou inflamação, composição farmacêutica, e, manufatura de um medicamento
EA200702026A1 (ru) Лечение или предупреждение зуда
BRPI0810773A2 (pt) Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição.
EA200800537A1 (ru) Маррубиин и композиция для уменьшения храпа, упаковка и методика
ATE416785T1 (de) Therapeutische anwendungen für c-peptid
ECSP066954A (es) Compuestos peptídicos para tratar dolor en neuropatía diabética dolorosa
ATE437624T1 (de) Topische zusammensetzungen
CL2004001603A1 (es) Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UCB PHARMA GMBH (DE)

Free format text: NOME ALTERADO DE: SCHWARZ PHARMA AG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.